AI Article Synopsis
- This study looked at something called MCP-1 in urine to see if it helps check if a transplanted kidney is being rejected.
- They found that people with kidney transplants who were rejecting their kidney had much higher levels of MCP-1 in their urine compared to those who were not rejecting it.
- Reducing MCP-1 levels happened after treatment, which suggests that measuring MCP-1 can help doctors know if a kidney is being rejected early on.
Article Abstract
Aim: To detect the content of monocyte chemotactic peptide-1(MCP-1) and to investigate the role of MCP-1 in acute renal graft rejection.
Methods: Urinary MCP-1 level was detected by avidin biotin complex(ABC)ELISA.
Results: Urinary MCP-1 levels in renal function stable renal transplantation of recipients and control group were (416+/-21) microg/L and (408+/-11) microg/L, respectively. Urinary MCP-1 level in renal transplantation recipients with acute rejection was (1195+/-58) microg/L, which was notably higher than that in control group and renal function stable recipients (P<0.01). After anti-rejection treatment, urinary MCP-1 level decreased markedly in patients who responded to treatment.
Conclusion: The urinary MCP-1 level is correlated closely with acute renal graft rejection and its increase may indicate ongoing acute renal rejection. Detection of urinary MCP-1 level may contribute to early diagnosis and prognostic judgement of acute graft rejection.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.
Medicine (Baltimore)
November 2024
Department of Endocrinology of Chongqing Red Cross Hospital (People's Hospital of Jiangbei District), Chongqing, China.
This study evaluates the effects of liraglutide on albuminuria, oxidative stress, and inflammation in type 2 diabetes (T2D) patients with different urinary albumin-to-creatinine ratio (UACR) categories. We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control. Patients were categorized into 3 groups: group I (UACR < 30 mg/g); group II (30 mg/g ≤ UACR ≤ 300 mg/g); group III (UACR > 300 mg/g).
View Article and Find Full Text PDFPrecision Medicine Proof-of-Concept Study of a TNF Inhibitor in FSGS and Treatment-Resistant Minimal Change Disease.
Kidney360
November 2024
Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Background: Focal segmental glomerulosclerosis (FSGS) and treatment-resistant minimal change disease (TR-MCD) are heterogeneous disorders with subgroups defined by distinct underlying mechanisms of glomerular and tubulointerstitial injury. A non-invasive urinary biomarker profile has been generated to identify patients with intra-kidney tumor necrosis factor (TNF)-activation and to predict response to anti-TNF treatment. We conducted this proof-of-concept, multi-center, open-label clinical trial to test the hypothesis that in patients with FSGS or TR-MCD and evidence of intra-renal TNF activation based on their biomarker profile, short-term treatment with adalimumab would reverse the elevated urinary excretion of MCP-1 and TIMP-1.
View Article and Find Full Text PDFUrinary RANTES and MCP-1 as noninvasive biomarkers for differential diagnosis and prediction of treatment response in acute interstitial nephritis.
Clin Kidney J
January 2025
Department of Medicine, Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background: Although kidney biopsy is definitive for the diagnosis of acute interstitial nephritis (AIN) and acute tubular necrosis (ATN), its invasiveness limits its use. We aimed to identify urine biomarkers for differentiating AIN and ATN and to predict the response of patients with AIN to steroid treatment.
Methods: In this prospective cohort study, biopsy-proven ATN ( = 34) and AIN ( = 55) were included.
Sepsis-Associated Acute Kidney Injury: What's New Regarding Its Diagnostics and Therapeutics?
Diagnostics (Basel)
December 2024
First Department of Internal Medicine, Sismanogleio General Hospital, 15126 Athens, Greece.
Sepsis-associated acute kidney injury (SA-AKI) is defined as the development of AKI in the context of a potentially life-threatening organ dysfunction attributed to an abnormal immune response to infection. SA-AKI has been associated with increased mortality when compared to sepsis or AKI alone. Therefore, its early recognition is of the utmost importance in terms of its morbidity and mortality rates.
View Article and Find Full Text PDFProlyl hydroxylase domain inhibitors prevent kidney crystal formation by suppressing inflammation.
Urolithiasis
December 2024
Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
The early stages of kidney crystal formation involve inflammation and hypoxia-induced cell injury; however, the role of the hypoxic response in kidney crystal formation remains unclear. This study investigated the effects of a prolyl hydroxylase domain inhibitor (roxadustat) on renal calcium oxalate (CaOx) crystal formation through in vitro and in vivo approaches. In the in vitro experiment, murine renal tubular cells (RTCs) were exposed to varying roxadustat concentrations and CaOx crystals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!